Lithium Ion

Lithium Ion

SCHEMBL6794513

O=C([O-])c1c2c(nn1CC(O)CN1CCCCC1)-c1ccncc1CC2.[Li+]

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
ABCB1 P08183 5/20 0.34
AURKA O14965 1/20 0.34
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34
CCNA1 P78396 1/20 0.34
CTSS P25774 9/20 0.33
ATM Q13315 1/20 0.33
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM4 P08173 1/20 0.32
CHRM3 P20309 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium Ion SCHEMBL6800533 0.99 PRMT5 (0.35) PRMT5WDR77ABCB1AURKACCNA2
Lithium Ion SCHEMBL6787009 0.91 PRMT5 (0.37) PRMT5WDR77ABCB1CTSSATM
SCHEMBL6794518 0.90 PLK1 (0.36) PRMT5WDR77ABCB1AURKACCNA2
SCHEMBL6800539 0.89 PRMT5 (0.36) PRMT5WDR77ABCB1AURKACCNA2
Lithium Ion SCHEMBL6793854 0.88 CTSS (0.37) PRMT5WDR77CTSSMEN1KMT2A
Lithium Ion SCHEMBL6792086 0.86 PRMT5 (0.37) PRMT5WDR77CTSS
Lithium Ion SCHEMBL6792451 0.84 AGER (0.35) MEN1KMT2A
Lithium Ion SCHEMBL6793578 0.84 CARM1 (0.36) PRMT5WDR77AURKACCNA2CDK2
SCHEMBL6787013 0.81 PRMT5 (0.38) PRMT5WDR77ABCB1CTSSATM
Hydrochloric Acid SCHEMBL6794118 0.81 CTSS (0.38) PRMT5WDR77CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 PHARMACIA CORPORATION 2004-07-01 US claimed
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 PHARMACIA CORPORATION 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 MKNK2, MAPKAPK2, MAP3K2 PRMT5 1416/4885WDR77 2717/4885ABCB1 3303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.